BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Special Report

All Special Reports
HIV KOL Interview

Retail Price: $599.00

*BioMedTracker Subscriber Price: $399.00 - click here to log in
July 03, 2017
We interviewed a US-based KOL who specializes in HIV treatment to gauge his views on marketed and pipeline drugs and current standard of care for HIV patients. The drugs discussed include ABX464, bictegravir (GILD), Darunavir/Emtricitabine/Cobicistat/TAF (JNJ), Descovy (GILD), doravirine (MRK), Edurant/Tivicay (GSK), Genvoya (GILD), GSK-1265744 LAP (GSK), ibalizumab (THERF), Isentress (MRK), Odefsey (GILD), PRO 140 (CYDY), Tivicay (GSK), Tivicay/Epivir (GSK), Triumeq (GSK) and Truvada (GILD).

If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only).

Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.

For our disclosures, please read the Biomedtracker Research Standards.

Indications Covered: HIV / AIDS